209P Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer
ESMO Rare Cancers · 2026-03 · 5 · 100415
DOI: 10.1016/j.esmorc.2026.100415 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESMO Rare Cancers, 2026-03. Verfasst von D. Orbach und 15 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pharmaceuticals Bayer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Pharmaceuticals Bayer
Zitieren
APA
Orbach, D., Xu, R., Qi, C., Zwaan, C., McDermott, R., Italiano, A., Tahara, M., Casanova, M., Burcoveanu, D., Guiver, K., Neu, N., Mussi, C., Cuesta, E. D. L., Laetsch, T., Drilon, A., & Hong, D. (2026). 209P Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer. ESMO Rare Cancers, 5, 100415. https://doi.org/10.1016/j.esmorc.2026.100415
Vancouver
Orbach D, Xu R, Qi C, Zwaan C, McDermott R, Italiano A, et al. 209P Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer. ESMO Rare Cancers. 2026;5:100415. doi:10.1016/j.esmorc.2026.100415
BibTeX
@article{Orbach2026,
author = {Orbach, D. and Xu, R-H. and Qi, C. and Zwaan, C.M. and McDermott, R.S. and Italiano, A. and Tahara, M. and Casanova, M. and Burcoveanu, D-I. and Guiver, K. and Neu, N. and Mussi, C. and Cuesta, E. De La and Laetsch, T. and Drilon, A. and Hong, D.},
title = {209P Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer},
journal = {ESMO Rare Cancers},
year = {2026},
volume = {5},
pages = {100415},
doi = {10.1016/j.esmorc.2026.100415}
}
EUVIMED